Skip to content
Back to outputs

IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas

Research output: Contribution to journalArticle

Standard

IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas. / Mihajluk, K.; Simms, C.; Reay, M.; Madureira, P. A.; Howarth, A.; Murray, P.; Nasser, S.; Duckworth, C. A.; Pritchard, D. M.; Pilkington, G. J.; Hill, R.

In: Cancer Letters, Vol. 458, 28.08.2019, p. 29-38.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Mihajluk, K. ; Simms, C. ; Reay, M. ; Madureira, P. A. ; Howarth, A. ; Murray, P. ; Nasser, S. ; Duckworth, C. A. ; Pritchard, D. M. ; Pilkington, G. J. ; Hill, R. / IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas. In: Cancer Letters. 2019 ; Vol. 458. pp. 29-38.

Bibtex

@article{3763f4b95d7f42028ed682a1141b707d,
title = "IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas",
abstract = "High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with conventional and novel anti-aHGG agents. We show that recent biopsy-derived aHGG models were highly resistant to conventional therapeutics although show sensitivity to IP1867B, a reformulated “liquid” aspirin. IP1867B treatment mediated a potent suppression of the IL6/STAT3 and NF-κB pathways and observed a significant reduction in EGFR transcription and protein expression. We observed the loss of the insulin-like growth factor 1 and insulin-like growth factor 1 receptor expression at both the transcript and protein level post IP1867B treatment. This increased sensitivity to EGFR inhibitors. In vivo, IP1867B was very well tolerated, had little-to-no gastric lesions versus aspirin and, directed a significant reduction of tumour burden with suppression of EGFR, IGF1 and IGFR1. With EGFR inhibitors, we noted a potent synergistic response in aHGG cells. These data provide a rationale for further investigation of IP1867B with a number of anti-EGFR agents currently being evaluated in the clinic.",
keywords = "adult high grade glioma, drug repurposing, EGFR, IGFR1",
author = "K. Mihajluk and C. Simms and M. Reay and Madureira, {P. A.} and A. Howarth and P. Murray and S. Nasser and Duckworth, {C. A.} and Pritchard, {D. M.} and Pilkington, {G. J.} and R. Hill",
year = "2019",
month = aug,
day = "28",
doi = "10.1016/j.canlet.2019.05.028",
language = "English",
volume = "458",
pages = "29--38",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas

AU - Mihajluk, K.

AU - Simms, C.

AU - Reay, M.

AU - Madureira, P. A.

AU - Howarth, A.

AU - Murray, P.

AU - Nasser, S.

AU - Duckworth, C. A.

AU - Pritchard, D. M.

AU - Pilkington, G. J.

AU - Hill, R.

PY - 2019/8/28

Y1 - 2019/8/28

N2 - High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with conventional and novel anti-aHGG agents. We show that recent biopsy-derived aHGG models were highly resistant to conventional therapeutics although show sensitivity to IP1867B, a reformulated “liquid” aspirin. IP1867B treatment mediated a potent suppression of the IL6/STAT3 and NF-κB pathways and observed a significant reduction in EGFR transcription and protein expression. We observed the loss of the insulin-like growth factor 1 and insulin-like growth factor 1 receptor expression at both the transcript and protein level post IP1867B treatment. This increased sensitivity to EGFR inhibitors. In vivo, IP1867B was very well tolerated, had little-to-no gastric lesions versus aspirin and, directed a significant reduction of tumour burden with suppression of EGFR, IGF1 and IGFR1. With EGFR inhibitors, we noted a potent synergistic response in aHGG cells. These data provide a rationale for further investigation of IP1867B with a number of anti-EGFR agents currently being evaluated in the clinic.

AB - High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with conventional and novel anti-aHGG agents. We show that recent biopsy-derived aHGG models were highly resistant to conventional therapeutics although show sensitivity to IP1867B, a reformulated “liquid” aspirin. IP1867B treatment mediated a potent suppression of the IL6/STAT3 and NF-κB pathways and observed a significant reduction in EGFR transcription and protein expression. We observed the loss of the insulin-like growth factor 1 and insulin-like growth factor 1 receptor expression at both the transcript and protein level post IP1867B treatment. This increased sensitivity to EGFR inhibitors. In vivo, IP1867B was very well tolerated, had little-to-no gastric lesions versus aspirin and, directed a significant reduction of tumour burden with suppression of EGFR, IGF1 and IGFR1. With EGFR inhibitors, we noted a potent synergistic response in aHGG cells. These data provide a rationale for further investigation of IP1867B with a number of anti-EGFR agents currently being evaluated in the clinic.

KW - adult high grade glioma

KW - drug repurposing

KW - EGFR

KW - IGFR1

U2 - 10.1016/j.canlet.2019.05.028

DO - 10.1016/j.canlet.2019.05.028

M3 - Article

VL - 458

SP - 29

EP - 38

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -

ID: 14386624